Navigation Links
Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
Date:1/8/2009

CLINTON, N.J., Jan. 8 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that its President & CEO, Daniel Tasse, will present at the 27th Annual JPMorgan Healthcare Conference on Wednesday, January 14, 2009 at 8:00 a.m., PST. The conference will be held January 12-15 at The Westin St. Francis Hotel in San Francisco.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns(1), and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

(1) INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more information on INOmax, including important safety information and full prescribing information, please visit www.inomax.com.

CONTACTS

    Samina Bari
    Ikaria
    (908) 238-6372
    samina.bari@ikaria.com 

    Jason Rando/Jen Saunders
    The Ruth Group
    (646) 536-7025/7011
    jrando@theruthgroup.com
    jsaunders@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
4. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
5. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. VivoMetrics to Present at the 2009 Biotech Showcase
7. OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal
8. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
9. Par Pharmaceutical to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):